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REVIEW
Background: Angiotensin-converting enzyme inhibitors (ACEI) have a well-established role
in the prevention of cardiovascular events in hypertension, left ventricular dysfunction, and
heart failure. More recently, ACEI have been shown to prevent cardiovascular events in
individuals with increased cardiovascular risk, where hypertension, left ventricular dysfunction,
or heart failure was not the primary indication for ACEI therapy.
Objective: To review studies of the effects of the ACEI perindopril on cardiovascular events.
Method: The EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in
Patients with Stable Coronary Artery Disease Study), PROGRESS (Perindopril Protection
Against Recurrent Stroke Study), and ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes
Trial – Blood Pressure Lowering Arm) trials are reviewed.
Results: Perindopril alone reduced cardiovascular events in subjects with stable coronary
heart disease. Perindopril in combination with indapamide reduced cardiovascular events in
subjects with cerebrovascular disease. Perindopril in combination with amlodipine reduced
cardiovascular events in subjects with hypertension.
Conclusion: Perindopril reduced cardiovascular events. The reduction of cardiovascular
events by perindopril was in large part associated with reduction of blood pressure, and greater
reduction in cardiovascular events was associated with greater reduction of blood pressure.
Perindopril may need to be combined with other antihypertensive agents to maximize reduction
of cardiovascular events.
Keywords: Angiotensin-converting enzyme inhibitor, hypertension, coronary heart disease,
stroke, myocardial infarction, heart failure
Introduction
Angiotensin-converting enzyme inhibitors (ACEI) have a well established role
in prevention of cardiovascular events in hypertension (Chobanian et al 2003;
BPLTTC 2005), left ventricular dysfunction (Flather et al 2000), and heart failure
(Flather et al 2000; Remme and Swedberg 2001; Hunt et al 2005). More recently,
ACEI have been shown to prevent cardiovascular events in individuals with
increased cardiovascular risk, where hypertension, left ventricular dysfunction,
or heart failure was not the primary indication for ACEI therapy (HOPE 2000;
PROGRESS 2001, 2003; EUROPA 2003). This review will summarise and
comment on three recent studies of the effects of the ACEI perindopril on
cardiovascular events, the EUROPA (European Trial on Reduction of Cardiac
Events with Perindopril in Patients with Stable Coronary Artery Disease Study)
and PROGRESS (Perindopril Protection Against Recurrent Stroke Study) studies
where the effects of perindopril were studied alone (PROGRESS 2001, 2003;
EUROPA 2003), or in combination with the diuretic indapamide (PROGRESS
2001, 2003), and the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial
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– Blood Pressure Lowering Arm) study where perindopril
was added to therapy with the calcium-channel blocker
amlodipine (Dahlof et al 2005).
ASCOT-BPLA provides no direct evidence about the
effects of perindopril on cardiovascular events (Dahlof et
al 2005). However, it does provide limited evidence for the
effect of perindopril in combination with amlodipine on
cardiovascular events. The vast majority of subjects
allocated to amlodipine-based therapy in ASCOT-BPLA
required one or more additional antihypertensive agents
which, for 59% of subjects, included perindopril. Thus,
perindopril played an essential role in blood pressure (BP)
reduction for most subjects allocated to the amlodipine-
based regimen.
EUROPA
EUROPA was a randomized placebo-controlled, double-
blind study of the effects of perindopril therapy on
cardiovascular events in 12 218 subjects with previous
myocardial infarction (MI), angiographic evidence of
coronary heart disease (CHD), coronary revascularization,
or a positive stress test (Table 1) (EUROPA 2003). Past
history of heart failure was recorded in 1.3% of subjects,
but none had clinical signs of heart failure, with 10% in
New York Heart Association class I and none in class II or
higher. Subjects were randomized to either 8 mg perindopril
or placebo.
It is notable that although only 27% of subjects had a
diagnosis of hypertension (BP > 160/95 mm Hg or receiving
antihypertensive treatment), the mean baseline systolic BP
(SBP) was 137 mm Hg, with a standard deviation of 16 mm
Hg, indicating that a sizable proportion were hypertensive
(Chobanian et al 2003). In comparison with placebo,
perindopril reduced BP by 5/2 mm Hg.
During a mean follow-up of 4.2 years, perindopril
reduced the primary outcome (composite of cardiovascular
death, non-fatal MI, cardiac arrest with successful
resuscitation) from 9.9% to 8.0% (20% decrease, 95%
confidence interval (CI) 9% to 29%; number needed to treat
(NNT)=53). The main contributor to this reduction in the
primary outcome was the reduction in non-fatal MI from
6.2% to 4.8% (22% decrease, 95% CI 10% to 33%;
NNT=74); the reduction in cardiovascular mortality from
4.1% to 3.5% (14% decrease, 95% CI -3% to 28%) did not
achieve statistical significance. The incidence of cardiac
arrest was only 0.2% with placebo and 0.1% with perindopril
(46% decrease, 95% CI -47% to 80%). Perindopril also
Table 1 Summary of EUROPA trial
Inclusion criteria: Men and women, aged >18 years, with CHD
(previous MI, PCI, CABG, or angiographic evidence*), and without
clinical evidence of heart failure. Men were also recruited if they had a
history of chest pain and a positive ECG, echocardiograph, or nuclear
stress test.
Exclusion criteria: Clinical evidence of heart failure, planned
revascularization, hypotension (SBP <110 mm Hg), uncontrolled
hypertension (SBP >180 mm Hg, DBP >100 mm Hg, or both), recent
use of ACEI or ARB, creatinine >0.15 mmol/L, serum potassium
>5.5 mmol/L.
Primary outcome: composite of cardiovascular death, non-fatal MI,
and cardiac arrest with successful resuscitation.
Secondary outcomes: composite of total mortality, non-fatal MI,
hospital admission for unstable angina, and cardiac arrest with
successful resuscitation; cardiovascular mortality and non-fatal MI, as
well as individual components of these secondary outcomes and
revascularization, stroke, and admission for heart failure.
Data derived from EUROPA 2003.
Baseline clinical Perindopril Placebo
characteristics (n=6110) (n=6108)
Age, years (SD) 60 (9) 60 (9)
Female sex 14.5% 14.7%
History of CHD
MI 64.9% 64.7%
PCI 29.0% 29.5%
CABG 29.3% 29.4%
Documented CHD
Angiographic evidence* 60.4% 60.5%
Positive stress test† 22.6% 23.3%
Previous stroke or TIA 3.4% 3.3%
Peripheral vascular disease 7.1% 7.4%
Hypertension‡ 27.0% 27.2%
Diabetes mellitus 11.8% 12.8%
Hypercholesterolemia§ 63.3% 63.3%
Medication
Platelet inhibitors 91.9% 92.7%
Lipid-lowering therapy 57.8% 57.3%
ß blockers 62.0% 61.3%
Calcium-channel blockers 31.7% 31.0%
Nitrates 42.8% 43.0%
Diuretics 9.1% 9.4%
SBP (SD) 137 (16) 137 (15)
*Angiographic evidence of CHD: stenosis > 70%. 
†Positive stress test: only in
men. 
‡Hypertension: BP > 160/95mm Hg or receiving antihypertensive
treatment. 
§Hypercholesterolemia: cholesterol > 6.5 mmol/L or receiving lipid-
lowering treatment.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB,
angiotensin type 1 receptor blocker; CABG, coronary artery bypass graft; CHD,
coronary heart disease; DBP, diastolic blood pressure; ECG, electrocardiograph;
PCI, percutaneous coronary intervention, MI, myocardial infarction; SBP, systolic
blood pressure; SD, standard deviation; TIA, transient ischemic attack.
reduced the incidence of heart failure requiring
hospitalization from 1.7% to 1.0% (39% decrease, 95% CI
17% to 56%; NNT=153), but produced only a slight
reduction in stroke from 1.7% to 1.6%. Perindopril producedVascular Health and Risk Management 2006:2(2) 119
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similar benefits in both hypertensive (BP >160/95 mm Hg
or receiving antihypertensive treatment on enrollment) and
nonhypertensive subjects.
Perindopril produced similar effects in EUROPA
participants with diabetes, although this substudy had
insufficient power to show statistical significance (Daly et
al 2005).
PROGRESS
The PROGRESS study was a randomized placebo-
controlled double-blind study of the effects of perindopril-
based therapy on stroke and other cardiovascular outcomes
in 6105 subjects with a history of ischemic or hemorrhagic
stroke, or transient ischemic attack within the previous 5
years (Table 2) (PROGRESS 2001, 2003). Active therapy
was 4 mg perindopril, with the addition of 2.5 mg
indapamide (2 mg in Japan) if the physician felt there was
no contraindication to a diuretic. Those for whom their
physician recommended single drug therapy were
randomized to receive either perindopril or single placebo.
Those for whom their physician recommended combination
drug therapy were randomized to receive either perindopril
plus indapamide or double placebo.
Whereas all PROGRESS participants had cerebro-
vascular disease, only 16% had CHD (history of MI or
coronary revascularization, or angina). While there were
no BP entry criteria, it was recommended that subjects
enrolled in PROGRESS have their hypertension
controlled by medication other than ACEI and
angiotensin type 1 receptor blocker (ARB) before
enrolment. Despite this recommendation, the mean SBP
on enrolment was 147 mm Hg, and 48% had SBP
>160 mm Hg or diastolic BP (DBP) >90 mm Hg
(PROGRESS 2001, 2003). Heart failure was an exclusion
criterion. In comparison with placebo, combination of
perindopril and indapamide during the PROGRESS trial
reduced BP by 12/5 mm Hg, whereas perindopril alone
reduced BP by 5/3 mm Hg.
During a mean follow-up of 3.9 years, the combination
of perindopril and indapamide reduced stroke incidence
from 14.4% to 8.4% (43% decrease, 95% CI 30% to 54%;
NNT=17), reduced major coronary events (non-fatal MI or
death ascribed to CHD) from 5.7% to 3.9% (35% decrease,
95% CI 12% to 52%; NNT=51), and reduced heart failure
incidence (hospitalization or requiring withdrawal of
randomized therapy) from 4.6% to 3.1% (34% decrease,
95% CI 7% to 53%; NNT=66). Perindopril alone produced
Table 2 Summary of PROGRESS trial
Inclusion criteria: Men and women, aged >18 years, with history of
stroke or TIA within the previous 5 years. Individuals with hypertension
treated with agents other than ACEI.
Exclusion criteria: Definite indication for treatment with ACEI (such
as heart failure); definite contraindication to treatment with ACEI (such
as previous intolerance).
Primary outcome: total stroke (fatal and non-fatal).
Secondary outcomes: fatal or disabling stroke; total major vascular
events comprising the composite of non-fatal stroke, non-fatal MI, or
death due to any vascular cause (including unexplained sudden death);
total and cause-specific deaths; and hospital admissions. Other
outcomes analyzed included major coronary events (defined as non-
fatal MI or death ascribed to CHD); total coronary events (non-fatal
MI, death ascribed to CHD, coronary revascularization (PCI, CABG), or
hospitalization due to unstable angina; congestive heart failure resulting
in death, hospitalization, or requiring withdrawal of randomized therapy.
Two subgroup analyses were prespecified: separate estimates of
treatment effects for combination (perindopril and indapamide)
therapy and single (perindopril alone) therapy; and separate estimates
of treatment effects for participants classified as hypertensive (SBP
>160 mm Hg or DBP >90 mm Hg) and those classified as
nonhypertensive at enrollment.
Data derived from PROGRESS 2001, 2003.
Baseline clinical Perindopril Placebo
characteristics (n=3051) (n=3054)
Age, years (SD) 64 (10) 64 (10)
Female sex 30% 30%
Asian* 39% 39%
Cerebrovascular disease history
Ischemic stroke 71% 71%
Cerebral hemorrhage 11% 11%
Unknown stroke 4% 5%
TIA or amaurosis fugax 22% 22%
CHD† 16% 16%
Peripheral vascular disease 4% 4%
Hypertension‡ 48% 48%
Atrial fibrillation 8% 8%
LVH on ECG 7% 7%
Diabetes mellitus 13% 12%
Current smoker 20% 20%
Medication
Platelet inhibitors 73% 72%
Statins 8% 8%
ß blockers 17% 18%
Calcium-channel blockers 40% 40%
Diuretics 11% 12%
Other antihypertensives 11% 12%
Oral anticoagulants 9% 10%
SBP (SD) 147 (19) 147 (19)
*Asian: participants recruited from People’s Republic of China or Japan; †history
of MI or coronary revascularization, or angina (supported by documented ECG
or angiographic evidence of coronary disease); ‡Hypertension: SBP ≥160mm Hg
or DBP ≥90 mm Hg.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; CABG,
coronary artery bypass graft; CHD, coronary heart disease; DBP, diastolic blood
pressure; ECG, electrocardiograph; LVH, left ventricular hypertrophy; PCI,
percutaneous coronary intervention, MI, myocardial infarction; SBP, systolic
blood pressure; SD, standard deviation; TIA, transient ischemic attack.Vascular Health and Risk Management 2006:2(2) 120
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non-statistically significant reductions in stroke incidence
from 12.9% to 12.3% (5% decrease, 95% CI – 19% to 23%),
major coronary events from 4.1% to 3.7% (7% decrease,
95% CI – 37% to 38%) and heart failure incidence from
5.4% to 4.5% (16% decrease, 95% CI – 19% to 41%). The
effects of perindopril-based therapy were similar for both
hypertensive (SBP ≥ 160 mm Hg or DBP ≥90 mm Hg on
enrollment) and nonhypertensive subjects.
ASCOT -BPLA
ASCOT-BPLA was a prospective randomized comparison
of amlodipine–perindopril and atenolol–bendro-
flumethiazide antihypertensive regimens on non-fatal MI
(including silent MI) and fatal CHD in 19 257 hypertensive
subjects with at least three other cardiovascular risk factors
(Table 3) (Dahlof et al 2005). The amlodipine-based regimen
was 5–10 mg amlodipine with addition of 4–8 mg
perindopril as required. The atenolol-based regimen was
50–100 mg atenolol with addition of 1.25–2.5 mg
bendroflumethiazide and potassium as required. By the end
of the study, most subjects were taking at least two
antihypertensive agents, and only 15% and 9% were taking
amlodipine and atenolol monotherapy, respectively. On
average, of total time, 83% were taking amlodipine as
allocated, 79% were taking atenolol, 59% were taking
perindopril, and 66% were taking bendroflumethiazide.
Overall, throughout the trial, a mean of 50% were taking
the combination of amlodipine with perindopril as allocated,
with or without other antihypertensive drugs. Compared
with those allocated to the atenolol-based regimen, BP
values were lower throughout the trial in those allocated to
the amlodipine-based regimen. These differences were
largest (5.9/2.4 mm Hg) at 3 months, and the average
difference throughout the trial was 2.7/1.9 mm Hg.
ASCOT-BPLA was stopped prematurely after 5.5 years’
median follow-up. Although the primary endpoint did not
achieve statistical significance, compared with the atenolol–
bendroflumethiazide regimen, individuals on the
amlodipine–perindopril regimen had 10% (95% CI - 2% to
21%) lower incidence of fatal CHD or non-fatal MI, 23%
(95% CI 11% to 34%; NNT=101) lower incidence of fatal
or non-fatal stroke, 16% (95% CI 10% to 22%; NNT=40)
lower incidence of total cardiovascular events and
procedures, and 11% (95% CI 1% to 19%; NNT=117) lower
all-cause mortality. However, the reduction in fatal and non-
fatal heart failure from 3.0% to 2.5% (16% decrease, 95%
Table 3 Summary of ASCOT-BLPA trial
Inclusion criteria: Men and women, aged 40–70 years, with either
untreated hypertension (SBP ≥ 160 mm Hg, DBP ≥1 00 mm Hg, or both)
or treated hypertension with SBP ≥ 140  mm Hg or DBP ≥ 90 mm Hg
or both. In addition, subjects had to have at least three of the following
cardiovascular risk factors: LVH, specified abnormalities on ECG, type 2
diabetes, peripheral arterial disease, previous stroke or TIA, male sex,
age ≥ 55 years, microalbuminuria or proteinuria, smoking, ratio of total/
HDL cholesterol ≥ 6, or family history of premature CHD.
Exclusion criteria: Previous MI, currently treated angina, a
cerebrovascular event within the previous 3 months, fasting
triglycerides >4.5 mmol/L, heart failure, uncontrolled arrhythmias, or
clinically important hematological or biochemical abnormality.
Primary outcome: composite of non-fatal MI (including silent MI)
and fatal CHD.
Secondary outcomes: all-cause mortality, total stroke, primary
outcome minus silent MI, all coronary events, total cardiovascular
events and procedures, cardiovascular mortality, and non-fatal and fatal
heart failure.
Data derived from Dahlof et al 2005.
Baseline clinical Amlodipine/ Atenolol/
characteristics Perindopril Bendroflumethiazide
(n=9639) (n=9618)
Age, years (SD) 63 (9) 63 (9)
Female sex 23% 23%
Previous stroke or TIA 11% 11%
Peripheral vascular disease 6% 6%
Diabetes mellitus 27% 27%
LVH 22% 22%
Atrial fibrillation 1% 1%
ECG abnormality other
than LVH 23% 23%
Other relevant
cardiovascular disease 6% 5%
Current smoker 33% 32%
Total cholesterol,
mmol/L (SD) 5.9 (1.1) 5.9 (1.1)
LDL cholesterol,
mmol/L (SD) 3.8 (1.0) 3.8 (1.0)
HDL cholesterol,
mmol/L (SD) 1.3 (0.4) 1.3 (0.4)
Triglycerides
mmol/L (SD) 1.8 (1.0) 1.9 (1.0)
Medication
Previous antihypertensive medications
None 19% 19%
1 44% 45%
≥ 2 36% 36%
Lipid-lowering therapy 11% 10%
Aspirin use 19% 19%
SBP, mm Hg (SD) 164 (18) 164 (18)
Abbreviations: CHD, coronary heart disease; DBP, diastolic blood pressure;
ECG, electrocardiograph; HDL, high density lipoprotein; LDL, low density
lipoprotein; LVH, left ventricular hypertrophy; PCI, percutaneous coronary
intervention, MI, myocardial infarction; SBP, systolic blood pressure; SD, standard
deviation; TIA, transient ischemic attack.Vascular Health and Risk Management 2006:2(2) 121
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CI - 5% to 34%) with the amlodipine–perindopril regimen
did not achieve statistical significance.
Why does perindopril reduce
cardiovascular events?
There is continuing debate about the role of BP reduction
in the prevention of cardiovascular events by BP-lowering
therapy. This debate is fuelled by studies showing decreases
in cardiovascular event rate greater than can be accounted
for by BP reduction (Lewis et al 1993; HOPE 2000;
EUROPA 2003). This debate is based in part on the
assumption that BP has a causal role in cardiovascular
disease pathogenesis. This assumption may not, however,
be correct, except in extreme situations such as flash
pulmonary edema due to acute severe elevation of BP.
Rather than cause cardiovascular events, elevated BP
may be the consequence of changes in the heart and
vasculature that overlap those that lead to cardiovascular
events (Figure 1). BP is the product of cardiac output (CO)
and systemic peripheral resistance (SVR). Thus, change in
BP is necessarily dependent upon change in cardiac and
vascular function that produces change in CO and/or SVR.
Many candidate mechanisms for the pathogenesis of
hypertension have been proposed (Guyton et al 1995;
Beevers et al 2001; Johnson et al 2002; Zandi-Nejad et al
2006), including the possible role of structural and functional
changes in the vasculature (Mark 1984; Noon et al 1997;
Simon 2004; Skov and Mulvany 2004; Wong et al 2004;
Safar and Boudier 2005; Ikram et al 2006). Moreover,
hypertension is associated with endothelial dysfunction and
other risk factors for cardiovascular disease (Lip et al 1995,
1999; Landray et al 2002; King et al 2004). Of particular
interest is the possibility that angiotensin II may participate
in the pathogenesis of both hypertension and cardiovascular
disease (Simon 2004).
BP may therefore have little if any causal role in the
pathogenesis cardiovascular events, and may show variable
change in response to cardiovascular disease-reducing
therapy. However, when this therapy does lower BP, even
within the normal range, it can serve as a valuable marker
of reduced cardiovascular risk. Most cardiovascular disease
is associated with BP levels below the current definition of
hypertension (WHO 2002), and there is a continuous
association between usual BP and cardiovascular event risk
down to 115 mm Hg SBP and 75 mm Hg DBP (PSC 2000).
There is ample evidence that perindopril has actions on
the heart and blood vessels that may reduce cardiovascular
disease. In addition to many studies in animals, studies in
humans show perindopril corrected endothelial dysfunction
(Bijlstra et al 1995; Watanabe et al 2005), and reduced
ventricular remodelling following MI (Ferrari et al 2006).
In addition, perindopril–indapamide improved arterial
stiffness and wave reflection, and reduced left ventricular
mass in hypertensive subjects (Asmar et al 2001; de Luca
et al 2004), and reduced albuminuria in diabetic subjects
(Mogensen et al 2003). Amlodipine–perindopril reduced
central pulse pressure more than atenolol in a substudy of
the ASCOT study, indicative of increased aortic compliance
(CAFE 2006).
The EUROPA investigators proposed the reduction in
cardiovascular events by perindopril in the EUROPA study
was greater than might be expected for the observed
reduction in BP (mean 5/2 mm Hg), and may have been due
to antiatherosclerotic effects of ACE inhibition. In contrast
to the EUROPA study, BP reduction was a key indicator of
reduced cardiovascular event rates in the PROGRESS study,
given the greater reductions in BP and cardiovascular events
seen with 4 mg perindopril in combination with indapamide,
than with 4 mg perindopril alone. The EUROPA study
suggests that 8 mg perindopril may have produced greater
reduction in cardiovascular events than produced by 4 mg
perindopril alone in the PROGRESS study. Conversely, the
PROGRESS data raise the possibility that a greater reduction
in cardiovascular events may have been seen in the EUROPA
study if perindopril had been combined with a diuretic.
Whereas analyses by the Blood Pressure Treatment
Trialists’ Collaboration suggest the size of the absolute BP
reduction is a more important indicator of the relative
cardiovascular disease-prevention by antihypertensive drugs
than is the antihypertensive drug choice, there are exceptions
Figure 1 Possible relationship between heart and blood vessel abnormalities
that influence cardiac output (CO) and systemic vascular resistance (SVR),
thereby influencing blood pressure (BP), and heart and blood vessel diseases
that cause cardiovascular events.
Antihypertensive
treatment
Abnormalities
of heart and
blood vessels
CO x SVR BP
Disease of
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emerging (BPLTT 2005). Thus, calcium channel blockers
appear to be inferior to other antihypertensive agents for
the prevention of heart failure (BPLTT 2005). Moreover,
data from the Losartan Intervention For Endpoint Reduction
(LIFE) study suggest losartan may provide better protection
from stroke than atenolol, although losartan- and atenolol-
based therapies had similar effects on cardiac outcomes
(Dahlof et al 2002). By contrast, the lower MI event rate
with amlodipine than valsartan therapy in the Valsartan
Antihypertensive Long-term Use Evaluation (VALUE)
study was associated with a greater BP reduction by
amlodipine (Julius et al 2004; Weber et al 2004).
Extensive analyses of the relationship between the
benefits of therapy and BP lowering in the ASCOT-BPLA
study provide indirect support for non-BP mechanisms
in mediating the superior prevention of cardiovascular
events by the amlodipine–perindopril regimen. Reduction
in cardiovascular events by the amlodipine–perindopril
regimen was associated not only with a greater reduction
of BP, but also with a faster pulse, and beneficial
alterations in body weight, serum high density lipoprotein
(HDL) cholesterol, triglycerides, creatinine, and
potassium, and fasting glucose levels (Poulter et al 2005).
All of these variables are independent risk factors for
cardiovascular events. When each of these variables was
analyzed separately for its effect on the difference
between the cardiovascular event rates for the two
treatment regimens, differences in HDL cholesterol had
the biggest association with differences in coronary event
rates, whereas only differences in BP were materially
associated with the stroke event rate. The effects of the
amlodipine–perindopril regimen, relative to the atenolol–
bendrofluthiazide regimen, on cardiovascular events were
attenuated, but remained statistically significant, when
analyses were adjusted for BP alone. However,
multivariate adjustment for all risk factors accounted for
half of the difference in coronary events and for about
40% of the difference in stroke events between the
amlodipine–perindopril and atenolol–bendrofluthiazide
regimens, and the residual differences in event rates were
no longer statistically significant (Poulter et al 2005).
The EUROPA investigators argued that some of the
benefits of lipophilic ACEI such as perindopril and
ramipril may be due to increased tissue penetration
(EUROPA 2003). However, the effects of ACEI are dose-
related (Campbell et al 1994), and studies in man showed
that although perindoprilat is more lipophilic, with more
rapid and efficient myocardial uptake than enalaprilat,
the two ACEI produced similar changes in angiotensin
and bradykinin peptide levels in arterial and coronary
sinus blood of humans with CHD (Zeitz et al 2003).
Should ACEI be given to all
patients with CHD?
Discussion of the EUROPA study has emphasized that the
benefits of perindopril were in addition to other preventive
measures, including the relatively high use of platelet
inhibitors (92%), β blockers (62%) and lipid lowering
therapy (58%) (EUROPA 2003). Nevertheless, the
Prevention of Events with Angiotensin Converting Enzyme
Inhibition (PEACE) trial suggests ACEI may have less
benefit in CHD if other preventive measures are more
effectively implemented (PEACE 2004). The PEACE study
was a randomized placebo-controlled double-blind study
of the effects of 4 mg trandolapril on cardiovascular events
in 8290 subjects with stable CHD and preserved left
ventricular function (PEACE 2004). During a median
follow-up of 4.8 years, trandolapril produced non-
statistically significant reductions in the primary endpoint
(composite of cardiovascular death, MI, and coronary
revascularization) from 22.5% to 21.9% (4% decrease, 95%
CI -6% to 12 %), and in cardiovascular death and non-fatal
MI from 8.5% to 8.3% (3% decrease, 95% CI -12% to 17%),
although trandolapril reduced hospitalization or death due
to heart failure from 3.7% to 2.8% (25% decrease, 95% CI
5% to 41%; NNT=112). However, BP (an indicator of
cardiovascular disease risk) at study baseline in PEACE
participants (133/78 mm Hg) was lower than the baseline
BP in the Heart Outcomes Prevention Evaluation (HOPE)
and EUROPA studies, and was similar to the level achieved
with ACEI therapy in HOPE and EUROPA. In addition,
PEACE participants received more intensive management
of risk factors than did those in the HOPE and EUROPA
studies, with 70% of PEACE participants receiving lipid
lowering therapy (29% in HOPE, 56% in EUROPA), and
72% had undergone coronary revascularization before
enrollment (40% in HOPE, 54% in EUROPA). Thus,
PEACE participants had an event rate similar to that of the
general population (1.6% annualized rate of death), and the
more aggressive management of their risk factors may have
negated any potential benefit from ACEI therapy (PEACE
2004). Pitt (2004) suggested that the lack of benefit from
trandolapril in the PEACE study may have been due to lower
low density lipoprotein (LDL) cholesterol levels in PEACE
participants. The Ischemia Management with Accupril postVascular Health and Risk Management 2006:2(2) 123
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bypass Graft via Inhibition of angiotensin converting
enzyme (IMAGINE) study similarly showed a lack of
benefit from 40 mg quinapril in optimally treated low-risk
patients after coronary artery bypass grafting (Keuper and
Verheugt 2005). The PEACE and IMAGINE studies
emphasize the importance of addressing modifiable risk
factors and incorporating an assessment of individual risks
and benefits in making decisions about ACEI therapy in
low risk patients with CHD and preserved left ventricular
function.
Another important benefit of ACEI and ARB therapy is
reduction of diabetes incidence (Hansson et al 1999; HOPE
2000; Dahlof et al 2002; PEACE 2004). Whether perindopril
reduces diabetes incidence is unknown, and combination
with indapamide may compromise any antidiabetic action
of perindopril. Current trials are of too short duration to
reveal the cardiovascular impact of diabetes prevention by
ACEI and ARB therapy. Given the increasing incidence of
diabetes and its contribution to cardiovascular disease,
prevention of diabetes may become one of the main
contributors to long-term cardiovascular benefit from ACEI
and ARB therapy in the future.
Conclusions
Perindopril reduces cardiovascular events. The reduction
of cardiovascular events by perindopril was in large part
associated with reduction of BP, and greater reduction of
BP was associated with greater reduction in cardiovascular
events. Perindopril may need to be combined with other
antihypertensive agents to maximize reduction of
cardiovascular events.
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